MEI Pharma Inc (MEIP) : Vivo Capital reduced its stake in MEI Pharma Inc by 60.22% during the most recent quarter end. The investment management company now holds a total of 1,101,129 shares of MEI Pharma Inc which is valued at $2,235,292 after selling 1,666,589 shares in MEI Pharma Inc , the firm said in a disclosure report filed with the SEC on Aug 15, 2016.MEI Pharma Inc makes up approximately 0.54% of Vivo Capital’s portfolio.
Other Hedge Funds, Including , Jacobs Levy Equity Management Inc reduced its stake in MEIP by selling 32,600 shares or 14.5% in the most recent quarter. The Hedge Fund company now holds 192,210 shares of MEIP which is valued at $390,186. MEI Pharma Inc makes up approx 0.01% of Jacobs Levy Equity Management Inc’s portfolio.Frigate Ventures Lp reduced its stake in MEIP by selling 613,300 shares or 24.97% in the most recent quarter. The Hedge Fund company now holds 1,842,493 shares of MEIP which is valued at $3,740,261. MEI Pharma Inc makes up approx 1.36% of Frigate Ventures Lp’s portfolio.Acrospire Investment Management boosted its stake in MEIP in the latest quarter, The investment management firm added 156 additional shares and now holds a total of 10,000 shares of MEI Pharma Inc which is valued at $20,600. MEI Pharma Inc makes up approx 0.01% of Acrospire Investment Management’s portfolio.
MEI Pharma Inc closed down -0.05 points or -2.79% at $1.74 with 4,71,063 shares getting traded on Thursday. Post opening the session at $1.78, the shares hit an intraday low of $1.71 and an intraday high of $1.83 and the price fluctuated in this range throughout the day.Shares ended Thursday session in Red.
MEI Pharma Inc. is an oncology company. The Company is focused on the clinical development of drugs and therapies for treatment of cancer. The Company’s portfolio of clinical drug candidates includes Pracinostat ME-344 and PWT143. Pracinostat is an orally available histone deacetylase (HDAC) inhibitor indicated for the treatment of advanced hematologic diseases such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). ME-344 is an isoflavone-based mitochondrial inhibitor targeting a mitochondrial component of the terminal respiratory chain complex in rapidly proliferating cells. PWT143 is an oral inhibitor of phosphatidylinositide 3-kinase (PI3K) delta a molecular target that plays a critical role in the proliferation and survival of hematologic cancer cells. Pracinostat has been tested in multiple Phase I and Phase II clinical trials in advanced hematologic malignancies and solid tumor indications.